Kardigan
CompanyUnited StatesFounded 2023
Kardigan develops one asset, in phase 3 (Danicamtiv in dilated cardiomyopathy). Mostly small molecule acting on MYH7; based in the United States, founded in 2023.
- 1
- Asset
- Furthest stage
- Phase 3
- 4
- Trials
- 3
- Signals
Pipeline
1Activates cardiac myosin to enhance heart muscle contraction.
Phase 3, Small molecule, MYH7, dilated cardiomyopathy, symptomatic genetic and familial dilated cardiomyopathy.
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials4
- Signals5
- Similar companies4